a look at these data gives me a lot of confidence in the phase III study. First, in GALAXY-1 the OS for all adenoca pts with Cox regression has p 0.04 with 90% CI .55 to .98. That is excellent for a phase II study that was not powered, as should be the case, to achieve statistical signicance. Secondly I think the data are poorly presented visually since the OS is the key parameter - they should at least have a bold vertical line on the Kaplan Meier curves showing the quite large differences. They do need some lessons in how to promote their data. Frankly, the thing that concerns me most is the selection of a subgroup with better prognosis for phase III, even though that makes some sense based on the available data. Wish they wouid have stuck to their guns. Hey, overexpression of Hsp90 is linked to poor prognosis. Based on the science, the poor prognosis patients are their ideal target population. Plus the failure to rely on primary outcome measures always raises suspicion, and in this case, resulted in a unreasonable negative response to the data. I made a big initial investment today and will buy more if the opportunity arises. I should mention that I'm nearly always right - I would have made a fortune in the market if I didn't find this stuff so boring.
Your comments are appreciated and interesting. If I understand correctly, you feel rapid progressors should have been included in Galaxy 2, calling them the "ideal target population." Could you explain, in layman's terms, why you feel this is the case despite the contrary data? Do you think the Galaxy 1 data was an anomaly, or that "long-tail" benefits have yet to kick-in for this group? What do you see that SNTA investigators don't?
"I'm nearly always right - I would have made a fortune in the market if I didn't find this stuff so boring"
ROFL. I remember saying that when I bought my first stock when I was 12 years old. LOL you just lost all credibility right there.
You can find me if you look up who sits on Federal Reserve chair now. Hence my peripheral interest in stock market. But now I do mostly money printing. I just mess with trolls on yahoo message board like others play Angry Bird - it really is too easy when you know your stuff.
You can find me if you look up who discovered the similarilty of the Hsp fold to actin. Hence my peripheral interest in Hsp rx. But now I do mostly clinical research. I just putter in stocks like others play puzzles. - it really is too easy when you know your stuff.
can you talk in layman terms?? that all went over my head.
Just tell me whats a good price to Re-short this so I can make some money trading this and profiting from the freefall???
Sentiment: Strong Sell